期刊文献+

吖啶类化合物在抗肿瘤方面的研究进展 被引量:11

Recent Progress of Acridine Derivatives with Antitumor Activity
原文传递
导出
摘要 吖啶类衍生物是一类含氮的有机杂环化合物,由于其在抗炎、抗菌及抗肿瘤方面体现了较好的生物活性而受到了广泛关注。本文对近年来吖啶类化合物在抗肿瘤方面的国内外研究成果进行了综述,对其主要作用靶点如端粒酶、拓扑异构酶Ⅰ/Ⅱ、微管蛋白、ABCG2/P-glycoprotein(P-gP)以及蛋白激酶等方面的研究进行了介绍,并指出该类化合物的发展方向及应用前景。 Acridines are a series of heterocyclic compounds, which have been received intense interest and used as anti-inflammatory, antibacterial and antitumour agents. This paper reviews some recent progresses in the research of the antitumor activity of acridine derivatives, including as the inhibition of telomerase, topoisomerases Ⅰ and Ⅱ , tubulin, ABCG2/P-gP, protein kinases, etc. The prospects and potential applications of such acridine compounds are outlooked.
出处 《化学进展》 SCIE CAS CSCD 北大核心 2012年第8期1497-1505,共9页 Progress in Chemistry
基金 国家自然科学基金项目(No.20902053) 国家高技术研究发展计划(863)项目(No.2012AA020305) 国家科技重大专项(No.2012ZX09506001-010) 国家重点基础研究发展计划(973)项目(No.2012CB722605) 国家国际科技合作项目(No.2011DFA30620)资助
关键词 吖啶 抗肿瘤 靶点 acridine antitumor drug targets
  • 相关文献

参考文献67

  • 1Belmont P, Constant J F, Demeunynck M. Chem. Soc. Rev. , 2001, 30:70-81.
  • 2Lagutschenkov A, Dopfer O. J. Mol. Spectrosc. , 2011, 268: 66-77.
  • 3Cholewiflski G, Dzierzbicka K, Ko~odziejczyk A M. Pharm. Rep. , 2011, 63:305-336.
  • 4Kaur J, Singh P. Expert Opin. Ther. Pat. , 2011, 21:437- 454.
  • 5姚成才,林从尧.端粒酶抑制剂与肿瘤治疗研究进展[J].肿瘤防治研究,2004,31(1):62-64. 被引量:3
  • 6Bi|sland A E, Cairney C J, Nicol K W. J. Cell. Mol. Med. , 2011, 15:179-186.
  • 7Harley C B, Futcher A B, Greider C W. Nature, 1990, 345: 458-460.
  • 8Kelland L R. Eur. J. Cancer, 2005, 41 : 971-979.
  • 9Neidle S. FEBS J., 2010, 277:1118-1125.
  • 10Campbell N H, Parkinson G N, Reszka A P, Neidle S. J. Am. Chem. Soe., 2008, 130:6722-6724.

二级参考文献17

  • 1赵永同,朱峰.凋亡的分子机理[J].生命科学,1996,8(2):19-23. 被引量:24
  • 2张莉萍.DNA拓朴异构酶及其抑制剂与细胞凋亡[J].国外医学(临床生物化学与检验学分册),1997,18(4):181-183. 被引量:6
  • 3Song Q, Lees-Miller SP, Kumar S, et al. DNA-dependent protein kinase catalytic subunit: A target for an ICE-like protease in apoptosis[J]. EMBO J, 1996, 15:3238.
  • 4John FB, Joyce AS, Thomas G. In vitro assays used to measure the activity of topoisomerases[J]. Antimicrob Agents Chemther,1990, 34(1):1.
  • 5Jacquelyne A, Kazuo A, Morgan AR. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage[J]. Molecular Pharmacology,1991, 40:495.
  • 6Christiansen K, Westerjaard O. Characterization of Intra- and Intermolecular DNA Ligation Mediated by Eukaryotic Topoisomerase I[J]. J Biol Chem, 1994, 269(1):721.
  • 7Froelich-Ammon SJ, Gale KC, Osheroff N, et al. Site-specific cleavage of a DNA Hairpin by TopoⅡ[J]. J Biol Chem,1994,269(10):7719.
  • 8Nicoletta Z, Alberto M, Patrizia S, et al. The 180-kDa Isoform of TopoisomeraseⅡIs Localized in the Nucleolus and Belongs to the Structural Elements of the Nucleolar Remnant[J]. Experimental Cell Research,1992, 200:460.
  • 9Xinbo Z, Jenn C, Bruce D, et al. Hoechst 33342 Induces Apoptosis in HL-60 Cells and Inhibits TopoisomeraseⅠIn Vivo[J]. Arch Pathol Lab Med, 1999,123:921.
  • 10Lansiaux A, Laine W, Baldeyrou B, et al. DNA topoisomerase II inhibition by peroxisomicine A(1) and its radical metabolite induces apoptotic cell death of HL-60 and HL-60/MX2 human leukemia cells[J]. Chem Res Toxicol, 2001, 14(1): 16.

共引文献16

同被引文献47

引证文献11

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部